227 related articles for article (PubMed ID: 24659749)
21. Nutlin-3a is a potential therapeutic for ewing sarcoma.
Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
[TBL] [Abstract][Full Text] [Related]
22. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
McCormack E; Haaland I; Venås G; Forthun RB; Huseby S; Gausdal G; Knappskog S; Micklem DR; Lorens JB; Bruserud O; Gjertsen BT
Leukemia; 2012 May; 26(5):910-7. PubMed ID: 22064349
[TBL] [Abstract][Full Text] [Related]
23. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
Long J; Parkin B; Ouillette P; Bixby D; Shedden K; Erba H; Wang S; Malek SN
Blood; 2010 Jul; 116(1):71-80. PubMed ID: 20404136
[TBL] [Abstract][Full Text] [Related]
24. Role of Mdm4 in drug sensitivity of breast cancer cells.
Lam S; Lodder K; Teunisse AF; Rabelink MJ; Schutte M; Jochemsen AG
Oncogene; 2010 Apr; 29(16):2415-26. PubMed ID: 20140020
[TBL] [Abstract][Full Text] [Related]
25. Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia.
Salomao N; Maslah N; Giulianelli A; Drevon L; Aguinaga L; Gu X; Cassinat B; Giraudier S; Fenaux P; Fahraeus R
Br J Haematol; 2023 Apr; 201(2):234-248. PubMed ID: 36546586
[TBL] [Abstract][Full Text] [Related]
26. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.
Vogel SM; Bauer MR; Joerger AC; Wilcken R; Brandt T; Veprintsev DB; Rutherford TJ; Fersht AR; Boeckler FM
Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16906-10. PubMed ID: 23035244
[TBL] [Abstract][Full Text] [Related]
27. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
28. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML.
Kojima K; Konopleva M; Samudio IJ; Schober WD; Bornmann WG; Andreeff M
Cell Cycle; 2006 Dec; 5(23):2778-86. PubMed ID: 17172851
[TBL] [Abstract][Full Text] [Related]
29. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
30. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia.
Vu TT; Stölzel F; Wang KW; Röllig C; Tursky ML; Molloy TJ; Ma DD
Leukemia; 2021 Jul; 35(7):1933-1948. PubMed ID: 33262524
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of MDM2 and MDM4 in virus-positive Merkel cell carcinoma enhances the p53 response.
Park DE; Cheng J; Berrios C; Montero J; Cortés-Cros M; Ferretti S; Arora R; Tillgren ML; Gokhale PC; DeCaprio JA
Proc Natl Acad Sci U S A; 2019 Jan; 116(3):1027-1032. PubMed ID: 30598450
[TBL] [Abstract][Full Text] [Related]
32. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
33. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous activation of p53 and inhibition of XIAP enhance the activation of apoptosis signaling pathways in AML.
Carter BZ; Mak DH; Schober WD; Koller E; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2010 Jan; 115(2):306-14. PubMed ID: 19897582
[TBL] [Abstract][Full Text] [Related]
35. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.
Carvajal LA; Neriah DB; Senecal A; Benard L; Thiruthuvanathan V; Yatsenko T; Narayanagari SR; Wheat JC; Todorova TI; Mitchell K; Kenworthy C; Guerlavais V; Annis DA; Bartholdy B; Will B; Anampa JD; Mantzaris I; Aivado M; Singer RH; Coleman RA; Verma A; Steidl U
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643228
[TBL] [Abstract][Full Text] [Related]
36. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
[TBL] [Abstract][Full Text] [Related]
37. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.
Fan C; Wang X
Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445
[TBL] [Abstract][Full Text] [Related]
38. Casein kinase 1α inhibits p53 downstream of MDM2‑mediated autophagy and apoptosis in acute myeloid leukemia.
Xu W; Huang Z; Gan Y; Chen R; Huang Y; Xue B; Jiang S; Yu Z; Yu K; Zhang S
Oncol Rep; 2020 Nov; 44(5):1895-1904. PubMed ID: 32901886
[TBL] [Abstract][Full Text] [Related]
39. Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5.
Carter BZ; Mak DH; Schober WD; Dietrich MF; Pinilla C; Vassilev LT; Reed JC; Andreeff M
Blood; 2008 Apr; 111(7):3742-50. PubMed ID: 18187663
[TBL] [Abstract][Full Text] [Related]
40. High levels of the p53 inhibitor MDM4 in head and neck squamous carcinomas.
Valentin-Vega YA; Barboza JA; Chau GP; El-Naggar AK; Lozano G
Hum Pathol; 2007 Oct; 38(10):1553-62. PubMed ID: 17651783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]